SUPT6H

Across TCGA pan-cancer cohorts, SUPT6H mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SUPT6H data layer compared with 22 for mass-spec protein and 14 for mutation status.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher SUPT6H mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SUPT6H expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

OV, HNSC, and PDAC are the cancer types where SUPT6H mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Tertile	All	0.497	0.844	.031	12	view →
HNSC	DFS	Median	All	0.559	0.739	.022	12	view →
PDAC	DFS	Tertile	IV	0.741	0.205	.024	3	view →
LUAD	OS	Quartile	III,IV	0.955	0.359	.035	3	view →
CCRCC	DFS	Quartile	All	0.819	0.966	.028	2	view →
LSCC	DFS	Median	III,IV	0.882	1.000	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SUPT6H–OV (DFS)

Open the OV breakdown →